B.C. has received research funding from Kura Oncology and the Leukemia Lymphoma Society, Octapharma and Syndax Pharmaceuticals and travel support from Octapharma and Syndax Pharmaceuticals. V.S. has acted (directly) as a consultant and/or adviser of Bayer, Daiichi Sankyo, Illumina, Incyte, Jazz Pharmaceuticals, Loxo Oncology/Lilly, Novartis and Relay Therapeutics, has acted as a consultant or adviser (with reimbursement to SCRI) of Abbvie, Agenus, Astex Pharmaceuticals, AstraZeneca, Bayer, Endeavor BioMedicine, Enlaza Therapeutics, Genmab, Hyku Biosciences, Incyte, Jazz Pharmaceuticals, LabGenius Limited, Lilly/Loxo Oncology, Merck, Nimbus Discovery, Novartis, Obsidian Therapeutics, PERS, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, Revolution Medicine, Roche, has received institutional research funding from Abbvie, Amgen, Arvinas, Bayer, Blueprint Medicines, Deciphera, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Incyte, Inhibrix, Loxo Oncology/Eli Lilly, Novartis, PharmaMar, Pfizer, OnCusp, Relay Therapeutics, Roche/Genentech, Synnovation Therapeutics, Takeda, Turning Point Therapeutics, Xencor, CME education funds from Clinical care communications, Medscape and OncLive, and personal travel expenses from AACR, ASCO and ESMO.